Topics in mTOR pathway and its inhibitors;Actualités sur la voie mTOR et ses inhibiteurs

Bulletin du Cancer

Volumn 96, Issue 1, 2009, Pages 87-94

  Dreyer, C ^a   Sablin, M P ^a   Faivre, S ^a   Raymond, E ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Deforolimus; Everolimus; Mtor; PI3K; Rapamycin; Temsirolimus

Indexed keywords

DEFOROLIMUS; EVEROLIMUS; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PERFOSIN; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AP-23573; DRUG DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL GROWTH; CLINICAL TRIAL; DRUG EFFICACY; DYSLIPIDEMIA; ENDOCRINE TUMOR; ENDOMETRIUM CANCER; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOMA; METASTASIS; PREDICTIVE VALIDITY; RASH; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT INDICATION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 61549122005     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0807     Document Type: Review

References (41)

1. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006 ; 5(8) : 671-88.
2. Alexandre J, Raymond E, Armand JP. La rapamycine et le CCI- 779. Bull Cancer 1999 ; 86(10) : 808-11.
3. Hartford CM, Ratain MJ. Rapamycin : something old, something new, something borrowed and now renewed. Clin Pharmacol The-rap 2007 ; 82(4) : 381-8.
4. Mounier N, Vignot S, Spano JP. Activité clinique du CCI779 (tem-sirolimus), inhibiteur de mTOR. Bull Cancer 2006 ; 93(11) : 1139-43.
5. Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006 ; 42 : 1875-80.
6. Pouessel D, Culine S. Angiogenesis targeting in renal carcinomas. Bull Cancer 2007 ; 94(7S) : F223-F226.
7. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 ; 356(22) : 2271-81.
8. Hess G, Romaguera JE, Verhoef G, Herbrecht R, Crump M, Strahs J, et al. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy. Proc Am Soc Clin Oncol 2008 (abstr 8513).
9. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005 ; 23 : 5314-22.
10. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al. Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus. Cancer Res 2006 ; 66(11) : 5549-54.
11. Oza AM, Elit L, Biagi J, Chapman W, Tsao M, Hedley D, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer. Proc Am Soc Clin Oncol 2006 (abst 3003).
12. Oza AM, Elit L, Provencher D, Biagi JJ, Panasci L, Sederias J, et al. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy : NCIC CTG IND 160b. Proc Am Soc Clin Oncol 2008 (abstr 5516).
13. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme : a north central cancer treatment group study. J Clin Oncol 2005 ; 23(23) : 5294-304.
14. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005 ; 23(4) : 357-61.
15. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J. CCI-779 in metastatic melanoma : a phase II trial of the California Cancer Consortium. Cancer 2005 ; 104(5) : 1045-8.
16. Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small-cell lung cancer who have responding or stable disease after induction chemotherapy : a trial of the Eastern Cooperative Oncology Group (El 500). ; Thorac Oncol 2007 ; 2(11) : 1036-41.
17. Okuno SH, Mahoney MR, Bailey HH, Adkins DR, Maples WJ, Ettinger D. A multicenter phase 2 consortium study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas. Proc Am Soc Clin Oncol (abstr 9504).
18. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma : a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 ; 372(9637) : 448-56.
19. Slomovitz BM, Lu KH, Johnston T, Munsell M, Ramondetta LM, Broaddus RR, et al. A phase II study of oral mammalian target of rapamycin(mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma. Proc Am Soc Clin Oncol 2008 (abstr 5502).
20. Ellard S, Gelmon KA, Chia S. A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer. Proc Am Soc Clin Oncol 2007 (abstr 3513).
21. Yao JC, Phan A, Chang DZ, Wolff RA, Jacobs C, Mares JE, et al. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma. Proc Am Soc Clin Oncol 2007 (abstr 4503).
22. Owonikoko TK, Stoller RG, Petro D, Flaugh R, Hershberger PA, Belani CP, et al. Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer. Proc Am Soc Clin Oncol 2008 (abstr 19017).
23. Rao RD, Allred JB, Windschitl HE, Maples J, McWilliams RR, Creagan ET, et al. N0377 : Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma. Proc Am Soc Clin Oncol 2007 (abstr 8530).
24. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly EK, Goldston M, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573 ; MK8669) administered intravenously daily for 5 days very 2 weeks to patients with advanced malignancies. J Clin Oncol 2008 ; 26(3) : 361-7.
25. Chawla SP, Tolcher AW, Staddon AP, Schuetze S, D'Amato GZ, Blay JY, et al. Survival results with AP23573, a novel inhibitor, in patients with advanced soft tissue or bone sarcomas : a phase II trial. Proc Am Soc Clinb Oncol 2006 (abstr 10076).
26. Colombo N, McMeekin S, Schwartz P, Kotzka J, Sessa C, Gehrig P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. Proc Am Soc Clin Oncol 2007 (abstr 5516).
27. Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3- Kinase/Akt/MammalianTarget of Rapamycin Pathway. Clin Cancer Res 2006 ; 12(3) : 679-89.
28. Birch R, Chawla S, Nemunaitis J, Savage P, Kaiser P, Spira A, et al. Perifosine as an active agent in the treatment of patients with advanced sarcoma. Proc Am Soc Clin Oncol 2007 (abstr 10059).
29. Stephenson J, Schreeder M, Waples J, Hargis J, Campos L, Birch R, et al. Perifosine, active as a single agent for renal cell carcinoma, now in phase I trials combined with tyrosine kinase inhibitors. Proc Am Soc Clin Oncol 2007 (abstr 15622).
30. Chee KG, Longmate J, Quinn Dl, Chatta G, Pinski J, Twardowski P, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer : a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007 ; 5(7) : 433-7.
31. Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG, et al. A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat 2008 ; 108(1) : 87-92.
32. Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland Jr. KM, Benson 3rd AB. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol 2007 ; 30(1) : 26-31.
33. Ernst DS, Eisenhauer E, Wainman N, Davis M, Lohmann R, Baetz T, et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 2005 ; 23(6) : 569-75.
34. Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, et al. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Therap 2006 ; 5(7) : 766-70.
35. Giessinger S, Amato RJ, Jac J, Saxena S, Willis JP, Chiang SB. A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) plus sorafenib for patients with metastatic renal cell cancer. Proc Am Soc Clin Oncol 2008 (abstr 14603).
36. Dumez H, Reichard P, Blay JY, Schöffski P, Morgan JA, Ray- Coquard IL, et al. A phase l-ll study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 2008 (abstr 10519).
37. Baselga J, Van Dam PA, Greil R, Gardner H, Bandearu R, Molloy B, et al. Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole ver sus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer. Proc Am Soc Clin Oncol 2008 (abstr 530).
38. Chollet P, Abrial C, Tacca O, Mouret-Reynier MA, Leheurteur M, Durando X, et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 2006 ; 7(4) : 336-8.
39. Lane HA, Lebwohl D. Future directions in the treatment of hormone-sensitive advanced breast cancer : the RAD001 (Everolimus)-letrozole clinical program. Semin Oncol 2006 ; 33(2 Suppl 7) : S18-25.
40. Whorf RC, Hainsworth JD, Spigel DR, Yardley DA, Burris HA, Waterhouse DM, et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2008 (abstr 5010).
41. Papadimitrakopoulou V, Blumenschein CR, Leighl NB, Bennouna J, Soria LC, Burris HA, et al. A phase1/2study investigating the combination of RAD001 (everolimus) and erlotinib as 2nd and 3rd line therapy in patients with advanced non-small cell lung cancer previously treated with chemotherapy : phase 1 results. Proc Am Soc Clin Oncol 2008 (abstr 8051).